The Ratings Game: ChemoCentryx shares soar on potential to upend standard of care in vasculitis

admin 4 years ago No Comments

This post was originally published on this site

A set of conclusive findings from a late-stage clinical trial testing ChemoCentryx Inc.’s experimental vasculitis treatment surprised company executives and investors, who now say they are bullish on the sales and pipeline potential of avacopan.

Prev Article Next Article

: Bank of America ordered to pay $250 million for fake accounts, junk fees and withholding credit card rewards

admin July 11, 2023

Earnings Results: DoorDash reports record Q2 sales but predicts slowing

admin August 12, 2021

Dow Jones Newswires: Toll Brothers sees strong demand drive 20% revenue growth in 2022

admin December 7, 2021

Key Words: Billionaire Ray Dalio has two looming concerns about Ukraine that should worry every investor

admin March 2, 2022

Dow Jones Newswires: AB InBev to book $1.1 billion impairment over sale of Russian JV stake

admin April 22, 2022

Election: Biden pledges to work for unity and combat the coronavirus in victory speech

admin November 8, 2020

About The Author

admin

Add Comment

in your inbox

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

By signing up above you will receive the Market Profit Center newsletter and 3rd party advertisements. Expect up to 5 messages per week from us. You can unsubscribe at any time at the bottom of any of our emails.

Related Posts

About The Author

admin

Add Comment